Mumbai, May 19 -- Zydus Lifesciences beat street estimates, with its revenue for the final quarter of 2025-26 rising 16% and net profit, adjusted for exceptional items, 15% year-on-year.

The Ahmedabad-based drugmaker projected high-teens growth in 2026-27, the company's top executive told investors in a post-earnings call on Tuesday.

For Q4FY26, its revenue from operations grew to Rs.7,587 crore, while adjusted net profit was Rs.1,593 crore. Ebitda grew 20% to Rs.2,554.4 crore, with margin expanding 110 basis points to 33.7%. Ebitda is short for earnings before interest, taxes, depreciation and amortization.

A Bloomberg poll of analysts estimated the March-quarter's revenue at Rs.7,024.4 crore and net profit at Rs.946.4 crore.

For FY2...